h
p
e
r
import
carbohydraterecogn
viral
surfac
glycoprotein
rang
clinic
import
viral
infect
identifi
number
protein
investig
possibl
drug
discoveri
target
part
investig
sever
protein
threedimension
structur
determin
either
nuclear
magnet
reson
spectroscop
xray
crystallograph
method
structur
inform
provid
excel
basi
structureassist
inhibitor
design
use
comput
chemistri
method
chapter
describ
signific
develop
field
structurebas
investig
viral
surfaceresid
carbohydraterecogn
protein
specif
overview
carbohydraterecogn
protein
four
import
human
virus
includ
influenza
dengu
rotaviru
parainfluenza
associ
structur
investig
present
virus
abl
replic
need
abl
adher
bind
invad
final
escap
suscept
host
cell
anim
host
cell
surfac
highli
decor
rang
glycan
structur
made
charg
neutral
carbohydr
gagneux
varki
carbohydr
involv
rang
differ
function
includ
cell
protect
host
recognit
event
cellcel
commun
gagneux
varki
consequ
elabor
host
cell
surfac
carbohydr
display
virus
develop
varieti
strategi
deal
protect
barrier
enabl
success
viral
propag
fact
mani
virus
activ
use
carbohydr
recognit
invas
process
life
cycl
understand
structur
viral
surfac
protein
vital
help
understand
function
also
enabl
design
new
drug
capabl
mitig
effect
caus
infect
influenza
viru
afflict
mankind
centuri
sever
major
pandem
report
includ
spanish
flu
end
world
war
kill
estim
million
peopl
taubenberg
et
al
recent
emerg
highli
pathogen
avian
influenza
viru
strain
although
easili
transmiss
human
report
mortal
rate
man
influenza
viru
contain
singlestrand
segment
rna
genom
member
orthomyxovirida
famili
subdivid
three
distinct
type
influenza
viru
b
c
van
regenmortel
et
al
concern
human
popul
type
b
type
like
caus
pandem
luschermattli
type
b
two
surfacebas
carbohydr
recogn
protein
involv
infecti
cycl
viru
name
haemagglutinin
ha
lectin
fusion
function
sialidas
also
known
neuraminidas
na
glycohydrolas
function
type
c
one
major
carbohydr
recogn
protein
haemagglutininesterasefus
protein
hef
combin
role
ha
na
influenza
b
herrler
et
al
current
major
way
combat
influenza
viru
b
infect
via
annual
vaccin
inject
howev
foolproof
gener
provid
protect
new
strain
influenza
viru
like
may
aris
avian
strain
also
avail
sever
drug
success
na
inhibitor
von
itzstein
relenza
tamiflu
see
howev
mutant
influenza
strain
resist
tamiflu
recent
detect
potenti
limit
avail
armament
clearli
necessit
ongo
search
new
treatment
von
itzstein
influenza
viru
c
common
caus
respiratori
tract
infect
gener
young
children
howev
case
may
lead
sever
infect
bronchiol
pneumonia
wagaman
et
al
crescenzochaign
van
der
werf
current
vaccin
specif
drug
treatment
influenza
c
influenza
viru
ha
homotrimer
glycosyl
protein
locat
surfac
virion
figur
respons
initi
figur
secondari
structur
influenza
viru
haemagglutinin
trimer
shown
transluc
surfac
surfac
colour
electrostat
potenti
red
denot
area
neg
charg
blue
denot
area
posit
charg
see
colour
plate
section
attach
virion
host
cell
surfac
recognit
termin
sialic
acid
moieti
chang
conform
protein
respons
initi
fusion
cell
membran
first
structur
influenza
viru
ha
publish
wilson
et
al
sinc
time
structur
variou
influenza
viru
deposit
research
collabatori
structur
bioinformat
rcsb
protein
data
bank
pdb
berman
et
al
earli
number
attempt
use
avail
crystal
structur
influenza
viru
ha
design
small
molecul
ha
binder
would
hope
inhibit
replic
influenza
viru
number
excel
review
appear
detail
attempt
luschermattli
matrosovich
klenk
howev
realiz
low
affin
sialic
acid
bind
site
would
produc
tight
bind
inhibitor
requir
drug
lead
design
synthesi
multival
polymer
inhibitor
inhibitor
howev
produc
suitabl
drug
candid
although
work
still
undertaken
ogata
et
al
marra
et
al
recent
studi
nandi
describ
silico
search
small
subset
zinc
databas
irwin
shoichet
led
suggest
possibl
small
molecul
inhibitor
ha
bind
although
biolog
evalu
compound
yet
report
avian
influenza
viru
ha
preferenti
recogn
termin
link
sialic
acid
contain
glycoconjug
wherea
humanadapt
influenza
viru
ha
preferenti
recogn
termin
link
sialic
acid
glycoconjug
recent
crystal
structur
viru
respons
pandem
gamblin
et
al
highli
pathogen
avian
influenza
strain
elucid
knowledg
structur
led
greater
understand
sialic
acid
specif
strain
appear
amino
acid
mutat
need
enabl
avian
influenza
viru
ha
switch
specif
recogn
human
receptor
yamada
et
al
recent
report
influenza
viru
may
recogn
receptor
accept
link
sialic
acid
observ
human
lower
respiratori
tract
rapoport
et
al
nichol
et
al
inspir
studi
may
complet
character
novel
asialoglycan
recognit
ha
exampl
von
itzstein
group
describ
nuclear
magnet
reson
nmr
spectroscopybas
studi
enabl
interrog
surfac
protein
viruslik
particl
novel
inhibitor
potenti
novel
glycan
structur
na
influenza
viru
b
major
focu
develop
drug
combat
influenza
infect
two
drug
alreadi
avail
market
name
structurebas
design
zanamivir
relenza
glaxosmithklin
oseltamivir
tamiflu
roch
develop
drug
adequ
review
elsewher
laver
von
itzstein
von
itzstein
influenza
viru
na
receptordestroy
enzym
cleav
ha
receptor
sialic
acid
rang
sialyloligosaccharid
allow
newli
form
viral
progeni
escap
surfac
infect
cell
go
infect
cell
influenza
viru
na
glycosyl
homotetram
tether
viru
surfac
long
protein
stalk
c
termin
figur
first
structur
influenza
viru
na
publish
varghes
et
al
exist
nearli
structur
current
pdb
includ
number
mutant
protein
well
number
inhibitorenzym
complex
inhibitorenzym
complex
particular
allow
studi
understand
interact
involv
design
new
inhibitor
combat
exist
mutat
influenza
virus
less
suscept
exist
drug
particularli
tamiflu
wealth
structur
inform
facilit
use
structurebas
drug
design
techniqu
dock
molecular
mechanicspoissonboltzmann
surfac
area
mmpbsa
simul
compar
molecular
field
analysi
comfa
etc
provid
explan
inhibitor
bind
influenza
viru
na
also
design
new
inhibitor
select
public
give
overview
use
techniqu
stoll
et
al
masukawa
et
al
armstrong
et
al
plati
et
al
zhang
et
al
abu
hammad
et
al
one
aspect
handl
consist
mani
studi
abil
protein
undergo
inducedfit
glycerol
side
chain
sialic
acidbas
inhibitor
zanamivir
replac
hydrophob
group
eg
activ
form
oseltamivir
oseltamivir
carboxyl
figur
exampl
accommod
hydrophob
group
oseltamivir
carboxyl
glutam
acid
residu
flip
form
intern
interact
arginin
result
hydrophob
pocket
previous
negativelycharg
hydrogen
bond
group
inducedfit
phenomena
easili
predict
inde
adequ
handl
theoret
model
reli
induc
fit
oseltamivir
carboxyl
also
make
hotspot
viru
gener
mutant
render
drug
less
abl
inhibit
receptordestroy
enzym
function
na
outcom
alreadi
observ
histidinetyrosin
mutant
oseltamivir
carboxyl
less
potent
compar
zanamivir
factor
less
potent
collin
et
al
one
interest
advanc
come
recent
na
structur
determin
analysi
exist
two
distinct
group
influenza
viru
na
group
russel
et
al
main
differ
group
appear
flexibl
activ
site
loop
includ
one
main
catalyt
residu
aspart
acid
group
na
consist
subtyp
flexibl
open
larg
new
pocket
activ
site
uncomplex
form
wherea
group
na
consist
show
movement
figur
current
commerci
avail
natarget
drug
design
group
na
gener
appear
equal
effect
group
na
govorkova
et
al
mishin
et
al
although
strain
variabl
observ
complic
current
avian
strain
exampl
group
na
induc
diseas
human
manifest
differ
normal
observ
human
influenza
diseas
result
higher
mortal
fact
strain
appear
common
spanish
flu
strain
healthier
individu
appear
suscept
usual
influenza
target
popul
old
young
immunocompromis
propos
direct
consequ
pandem
pandemiclik
virus
abil
caus
immun
event
refer
cytokin
storm
peiri
et
al
hef
influenza
viru
c
structur
similar
ha
found
surfac
influenza
viru
b
homotrimer
glycosyl
surfac
protein
major
differ
receptor
recogn
sialic
acidcontain
glycoconjug
recogn
ha
sialic
acidglycoconjug
recogn
hef
ii
fact
hef
contain
lectin
function
well
receptordestroy
enzym
contrast
influenza
viru
b
two
distinct
protein
function
receptordestroy
enzym
hef
esteras
cleav
oacet
group
sialic
acid
crystal
structur
hef
publish
rosenth
et
al
receptordestroy
enzym
activ
site
similar
natur
serin
esteras
complet
separ
receptorbind
site
model
experi
use
forc
glycosid
angl
torsion
search
help
explain
nmr
result
obtain
recent
within
von
itzstein
group
mayr
et
al
hef
bovin
coronaviru
esteras
led
understand
essenti
pharmacophor
group
requir
bind
receptordestroy
enzym
activ
site
knowledg
aglycon
group
appear
involv
substrat
bind
site
similar
haemagglutinin
esteras
homolog
also
identifi
corona
torovirus
de
groot
although
virus
close
relat
influenza
viru
c
understand
structur
function
haemagglutinin
esteras
provid
inform
mechan
cell
recognit
entri
influenza
viru
adapt
resist
mutant
alreadi
appear
least
one
commerci
avail
na
inhibitor
ongo
structur
comput
studi
surfaceresid
carbohydr
recogn
protein
help
identifi
new
potent
drug
also
understand
fulli
mechan
action
protein
especi
interest
group
na
includ
current
avian
influenza
flexibl
loop
activ
site
provid
antiinfluenza
drug
design
anoth
target
improv
potenc
exist
drug
chanc
develop
new
group
drug
paramyxovirida
famili
includ
member
human
parainfluenza
virus
newcastl
diseas
viru
measl
mump
virus
lamb
et
al
particular
interest
human
parainfluenza
virus
newcastl
diseas
viru
surfaceresid
carbohydr
recogn
protein
known
haemagglutininneuramindas
hn
involv
cellular
recognit
receptordestroy
enzym
lamb
et
al
four
human
parainfluenza
virus
hpiv
strain
identifi
caus
respiratori
tract
symptom
eg
cough
wheez
predominantli
infant
human
parainfluenza
virus
consid
second
import
caus
lower
respiratori
tract
diseas
young
children
behind
respiratori
syncyti
viru
henrickson
strain
commonli
associ
respiratori
tract
diseas
croup
caus
bronchiol
pneumonia
rare
detect
henrickson
newcastl
diseas
viru
also
known
avian
paramyxoviru
devast
effect
poultri
industri
worldwid
seal
et
al
similar
hef
influenza
viru
c
hn
includ
recognit
element
termin
sialic
acid
well
receptordestroy
sialidaseneuraminidas
function
facilit
virion
bud
first
crystal
structur
hn
newcastl
diseas
viru
publish
crennel
et
al
show
similar
influenza
viru
na
overal
shape
activ
site
configur
howev
activ
site
appear
flexibl
probabl
allow
function
sialic
acidrecogn
lectin
na
recent
newcastl
diseas
viru
hn
structur
zaitsev
et
al
reveal
presenc
second
sialic
acid
bind
site
propos
involv
fusion
process
initi
recognit
sialic
acid
time
newcastl
diseas
viru
hn
structur
avail
structur
structurebas
drug
design
inhibitor
human
parainfluenza
virus
led
two
report
design
inhibitor
enzym
system
alymova
et
al
tindal
et
al
studi
made
use
acid
templat
also
precursor
influenza
viru
na
inhibitor
relenza
also
target
larg
caviti
around
bind
region
templat
best
inhibitor
led
micromolar
inhibit
na
function
seriou
human
parainfluenza
virus
ie
crystal
structur
report
one
design
inhibitor
ryan
et
al
complex
newcastl
diseas
viru
hn
demonstr
ligand
bound
activ
site
predict
manner
figur
recent
sever
crystal
structur
hn
publish
lawrenc
et
al
although
best
knowledg
structurebas
drug
design
studi
report
furthermor
crystal
structur
hn
formerli
known
simian
viru
publish
yuan
et
al
reveal
overal
architectur
appear
similar
newcasl
diseas
viru
addit
provid
drug
design
opportun
hn
structur
along
structur
fusion
f
protein
provid
inform
mechan
cell
entri
famili
virus
lead
greater
understand
virus
propag
make
easier
combat
spread
origin
structurebas
drug
design
studi
antihuman
parainfluenza
viru
drug
base
avail
newcastl
diseas
viru
hn
structur
detail
design
work
undertaken
use
structur
also
number
nonsial
acid
base
templat
use
develop
influenza
viru
na
eg
cyclohexen
cyclopentan
pyrrolidin
altern
templat
could
use
structurebas
drug
design
process
extend
rang
compound
potenti
hn
inhibitor
flavivirus
member
flavivirida
famili
transmit
human
either
mosquito
tick
bite
solomon
mallewa
flavivru
infect
lead
number
sever
debilit
symptom
eg
feverarthralgiarash
viral
haemorrhag
fever
neurolog
diseas
solomon
mallewa
mosquitoborn
virus
includ
dengu
viru
denv
four
strain
yellow
fever
viru
west
nile
viru
japanes
enceph
viru
tickborn
virus
includ
tickborn
enceph
viru
langat
viru
omsk
haemorrhag
fever
viru
surfac
flaviviru
predominantli
cover
eglycoprotein
egp
form
dimer
tether
surfac
stalk
region
egpassoci
glycan
viru
shown
import
denv
infect
interact
dendrit
cellspecif
nonintegrin
dcsign
navarrosanchez
et
al
tassaneetrithep
et
al
see
chapter
interact
involv
life
cycl
recent
review
perera
et
al
note
egp
major
site
host
cell
receptor
bind
hostmedi
antibodi
neutral
mosquito
tickborn
viru
egp
share
signific
sequenc
structur
homolog
crystal
structur
egp
sever
sourc
show
compris
three
distinct
domain
figur
name
modi
et
al
zhang
et
al
modi
et
al
tickborn
enceph
viru
rey
et
al
bind
fusion
process
egp
dimer
dissoci
reform
trimer
structur
trimer
fusion
state
also
avail
ie
modi
et
al
tickborn
enceph
viru
bressanelli
et
al
west
nile
viru
three
domain
found
domain
mostli
respons
viru
bind
target
host
cell
crill
roehr
also
shown
block
viru
bind
addit
crystal
structur
mention
structur
subunit
huang
et
al
volk
et
al
west
nile
viru
volk
et
al
japanes
enceph
viru
wu
et
al
langat
viru
wu
et
al
haemorrhag
fever
viru
volk
et
al
determin
nmr
spectroscop
techniqu
receptor
egp
definit
establish
previou
studi
identifi
glycosaminoglycan
heparan
sulfat
rang
protein
speci
propos
mammalian
cell
surfac
receptor
clyde
et
al
recent
work
aoki
et
al
shown
associ
denv
mammalian
cell
surfac
glycolipid
paraglobosid
suggest
egp
particular
carbohydraterecogn
protein
small
variat
sequenc
member
famili
lead
differ
cell
receptor
avail
structur
differ
flavivirus
also
allow
us
come
greater
understand
variou
neutral
antibodi
bind
egp
wu
et
al
nybakken
et
al
kaufmann
et
al
gromowski
barrett
facilit
design
possibl
therapeut
capabl
halt
spread
arthropodborn
virus
figur
access
avail
structur
molecular
model
techniqu
exampl
blind
autodock
hetenyi
van
der
spoel
satur
transfer
differ
std
nmr
spectroscop
techniqu
mayer
meyer
haselhorst
et
al
b
combin
glycan
array
studi
day
et
al
provid
excit
opportun
identif
host
cell
base
glycan
receptor
also
character
bind
site
inform
combin
structurebas
drug
design
techniqu
appli
search
possibl
inhibitor
initi
recognit
bind
event
involv
cellular
invas
arthropodborn
virus
present
influenza
viru
ha
exampl
small
moleculebas
inhibitor
may
bind
suffici
affin
produc
entiti
capabl
prevent
viru
replic
howev
multival
inhibitor
may
provid
valuabl
altern
rotaviru
member
reovirida
famili
frequent
caus
agent
sever
diarrhoea
young
children
account
hospit
admiss
diarrhoea
death
everi
year
glass
et
al
advanc
develop
vaccin
made
heys
et
al
human
popul
question
safeti
efficaci
still
remain
franco
greenberg
furthermor
rotaviru
also
impact
product
livestock
industri
yu
et
al
therefor
work
need
better
understand
rotaviru
lifecycl
carbohydr
involv
drug
new
vaccin
develop
opportun
rotaviru
virion
surfac
spike
protein
respons
receptor
bind
cell
penetr
ludert
et
al
zarat
et
al
aria
et
al
protein
cleav
trypsin
ntermin
figur
superimposit
avail
flaviviru
domain
structur
green
red
blue
japenes
enceph
viru
cyan
langat
viru
magenta
omsk
haemorrhag
fever
viru
yellow
tickborn
enceph
viru
brown
west
nile
viru
surfac
repres
remain
portion
egp
dimer
colour
electrostat
potenti
major
differ
seen
loop
tickborn
enceph
viru
omsk
haemorrhag
fever
viru
langat
viru
bulg
residu
delet
loop
portion
protein
see
colour
plate
section
rotaviru
fragment
shown
respons
haemagglutin
fragment
believ
involv
cellular
fusion
fior
et
al
ciarlet
et
al
graham
et
al
controversi
absolut
requir
sialic
acid
initi
bind
viru
cell
surfac
delorm
et
al
ciarlet
et
al
isa
et
al
current
rotaviru
strain
classifi
either
sialidasesensit
ie
longer
infect
sialidasetr
cell
infer
sialic
acid
depend
infect
sialidaseinsensit
infect
cell
regardless
sialidas
treatment
therebi
suggest
sialic
acid
independ
infect
examin
carbohydr
recognit
first
structur
nmr
xray
rhesu
rotaviru
strain
sialidasesensit
publish
dormitz
et
al
subsequ
crystal
structur
number
nativ
sitedirect
mutant
rhesu
rotaviru
protein
report
kraschnefski
et
al
structur
sialidasesensit
strain
publish
porcin
strain
blanchard
et
al
crystal
structur
protein
includ
ligand
figur
bind
site
show
sugar
ring
posit
two
tyrosin
tyr
residu
carboxyl
acid
moieti
sialic
acid
form
hydrogen
bond
serin
ser
residu
final
arginin
arg
residu
form
hydrogen
bond
glycerol
side
chain
sialic
acid
sialic
acid
bind
motif
differ
seen
influenza
viru
haemagglutinin
sialidas
report
sever
sialyllewi
x
recogn
bacteri
toxin
baker
et
al
structur
investig
relev
human
rotaviru
infect
two
structur
protein
sialidaseinsensit
human
strain
wa
kraschnefski
et
al
blanchard
et
al
monnier
et
al
determin
final
recent
public
yu
et
al
describ
crystal
preliminari
xray
diffract
analysi
protein
sialidasesensit
bovin
rotaviru
strain
ncdv
molecular
model
std
nmr
experi
within
group
haselhorst
et
al
shown
good
correl
bind
number
sialic
acid
deriv
rhesu
rotaviru
degre
compound
inhibit
rotaviru
infect
cell
also
inform
obtain
bind
epitop
sialic
acid
disaccharid
show
penultim
sugar
residu
interact
protein
remain
predominantli
solvat
good
agreement
molecular
dynam
calcul
show
sugar
galactos
unabl
adopt
conform
close
proxim
surfac
haselhorst
et
al
knowledg
bind
site
ligand
protein
human
rotaviru
strain
provid
excit
opportun
design
inhibitor
prevent
viru
entri
infect
exampl
use
comput
chemistri
method
explor
avail
structur
data
combin
techniqu
nmr
spectroscopi
invalu
advanc
role
carbohydr
rotaviru
lifecycl
larg
number
clinic
import
virus
util
carbohydr
viral
surfac
protein
interact
propag
infect
diseas
identif
structur
character
protein
glycan
essenti
recognit
phenomena
open
new
avenu
drug
discoveri
vaccin
develop
limit
number
viral
surfac
protein
structur
determin
alreadi
structurebas
drug
design
techniqu
afford
new
class
drug
although
signific
advanc
made
target
viru
surfac
glycoprotein
discoveri
drug
remain
urgent
need
investig
research
focu
box
scienc
glycovirolog
still
infanc
show
great
promis
deliveri
new
weapon
pathogen
drug
treatment
avail
identif
next
gener
influenza
viru
sialidas
inhibitor
requir
replac
exist
drug
resist
develop
understand
carbohydr
recognit
process
involv
dengu
viru
rotaviru
infect
necessari
enabl
develop
use
chemotherapeut
agent
systemat
investig
hostviru
carbohydr
recognit
phenomena
would
greatli
enhanc
field
refer
